The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL

Basit Öğe Kaydı
dc.authorscopusid14219156500
dc.authorscopusid55212747300
dc.authorscopusid57217304190
dc.authorscopusid57194114271
dc.authorscopusid57190865932
dc.authorscopusid56370690600
dc.authorscopusid57208321258
dc.contributor.authorAkpınar, Seval
dc.contributor.authorDoğu, Mehmet Hilmi
dc.contributor.authorÇelik, Serhat
dc.contributor.authorEkinci, Ömer
dc.contributor.authorYönal Hindilerden, İpek
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorAltuntaş, Fevzi
dc.contributor.authorTurgut, Burhan
dc.date.accessioned2022-05-11T14:05:03Z
dc.date.available2022-05-11T14:05:03Z
dc.date.issued2022
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractIntroduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/Methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the participating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+/p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were ? grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atrial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare during the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS. Conclusion: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. © 2021 Elsevier Inc.
dc.description.sponsorshipThe authors thank all the staff of the medical centers who contributed in any way to the collection of the data.
dc.identifier.doi10.1016/j.clml.2021.09.010
dc.identifier.endpage173
dc.identifier.issn2152-2650
dc.identifier.issue3en_US
dc.identifier.pmid34629286
dc.identifier.scopus2-s2.0-85116827763
dc.identifier.scopusqualityQ2
dc.identifier.startpage169
dc.identifier.urihttps://doi.org/10.1016/j.clml.2021.09.010
dc.identifier.urihttps://hdl.handle.net/20.500.11776/4881
dc.identifier.volume22
dc.identifier.wosWOS:000760119700011
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAkpınar, Seval
dc.institutionauthorTurgut, Burhan
dc.language.isoen
dc.publisherElsevier Inc.
dc.relation.ispartofClinical Lymphoma, Myeloma and Leukemia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBruton tyrosine kinase
dc.subjectChronic lymphocytic leukemia
dc.subjectIbrutinib
dc.subjectp53 mutation
dc.subjectRelapsed/refractory
dc.subjectibrutinib
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectatrial fibrillation
dc.subjectbleeding
dc.subjectcancer recurrence
dc.subjectcancer staging
dc.subjectchronic lymphatic leukemia
dc.subjectcohort analysis
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectcytogenetics
dc.subjectdemography
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectdrug tolerability
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjecthypertension
dc.subjectleukemia relapse
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmulticenter study
dc.subjectmulticenter study (topic)
dc.subjectneutropenia
dc.subjectoverall survival
dc.subjectpneumonia
dc.subjectretrospective study
dc.subjectthrombocytopenia
dc.subjecttreatment response
dc.titleThe Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu